Equities researchers at UBS Group started coverage on shares of Cyclerion Therapeutics (NASDAQ:KRSA – Get Free Report) in a research note issued to investors on Friday, Benzinga reports. The brokerage set a “buy” rating and a $55.00 price target on the stock.
Separately, Zacks Research raised Cyclerion Therapeutics to a “hold” rating in a research report on Wednesday. One research analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $55.00.
View Our Latest Stock Report on KRSA
Cyclerion Therapeutics Stock Performance
Cyclerion Therapeutics Company Profile
Cyclerion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for serious diseases of the central nervous system. The company has concentrated on therapies designed to influence the nitric oxide–soluble guanylate cyclase signaling pathway, which may play a role in neurological and other debilitating conditions.
Cyclerion’s lead development program was IW-6463, an oral, central nervous system-penetrant soluble guanylate cyclase stimulator investigated for potential use in neurodegenerative diseases, including Alzheimer’s disease and amyotrophic lateral sclerosis.
Read More
- Five stocks we like better than Cyclerion Therapeutics
- Feed to Feat: Can Meta Unlock the AI Agent Cash Machine?
- Chime Finds Its Stride With a $590M Deal That Could Reshape Its Banking Model
- IBM and Lockheed Martin Turn a Swiss Defense Deal Into a Quantum Computing Bet
- AeroVironment’s Record Backlog and Earnings Beat Fuel Recovery Case
Receive News & Ratings for Cyclerion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclerion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
